NAPLES, Fla., June 3, 2021 /PRNewswire/ -- Enveric
Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a
patient-first biotechnology company developing novel naturally
occurring medicines to improve quality of life for cancer patients,
and MagicMed Industries ("MagicMed"), a privately-held
biotechnology company focused on creating a library of novel
derivative psychedelic molecules such as psilocybin,
N,N-dimethyltryptamine (DMT) and other molecular derivatives with
applications across multiple indications, today announced that
David Johnson, Chairman and Chief
Executive Officer of Enveric, and Dr. Joseph Tucker, Chief Executive Officer of
MagicMed, will be participating in the following investor and
industry conferences in June.
On May 24, 2021, Enveric announced
a definitive agreement to acquire MagicMed. In June, the
senior leadership teams of Enveric and MagicMed along with the
MagicMed research and development team will participate in several
investor and industry conferences.
Benzinga Capital Conference
Dr. Joseph Tucker, President and CEO of MagicMed
Friday, June 4th at
9:50 a.m. ET
Registration:
https://www.benzinga.com/events/cannabis/virtual/
LD Micro Invitational XI
David Johnson, Chairman and CEO of Enveric
Tuesday, June 8th at
2:30 p.m. ET
Registration: https://ldmicrojune2021.mysequire.com
Emerging Growth Conference
David Johnson, Chairman and CEO of Enveric
Wednesday, June 9th at
12:00 p.m. ET
Registration:
https://goto.webcasts.com/starthere.jsp?ei=1469230&tp_key=f8b5116237&sti=envb
Bio Digital Conference
Dr. Joseph Tucker, President and CEO of MagicMed
June 10th-11th
and June
14th-18th
Registration:
https://www.bio.org/events/bio-digital
H. C. Wainwright Conference: Psychedelics in Psychiatry and
Beyond
Dr. Joseph Tucker,
President and CEO of MagicMed
Panel: Drug Discovery and Development of Psychoactive Agents for
Psychiatry and Beyond
Thursday, June 17th at
12:00 p.m. ET
Registration: https://hcwevents.com/psychedelics/
Psychedelic Opportunity Summit
Dr. Joseph Tucker, President and CEO of MagicMed
Tuesday, June 22nd at
3:15 p.m. ET
Panel: The Power of Derivative Molecules for Treating Brain
Health
Registration:
https://momentumevents.com/psychedelicevent/agenda/
For more information regarding each conference, or to schedule a
one-on-one meeting with Enveric and MagicMed management, please
visit the sponsor's conference website or contact KCSA Strategic
Communications at EnvericBio@kcsa.com.
About Enveric Biosciences
Enveric Biosciences is a patient-first biotechnology company
developing rigorously tested, novel naturally occurring medicines
to improve quality of life for cancer patients. Initial indications
include radiodermatitis, a common and often severe side effect of
radiation therapy, and chemotherapy-induced neuropathy. For more
information, please visit https://www.enveric.com/.
About MagicMed
MagicMed Industries intends to partner with pharmaceutical and
other companies to develop and commercialize psychedelic-derived
pharmaceutical candidates. MagicMed's psychedelic derivatives
library, the Psybrary™, is anticipated to be an essential building
block from which industry can develop new patented products. The
initial focus of the Psybrary™ is on psilocybin and DMT
derivatives, and it is then expected to be expanded to other
psychedelics such as MDMA, LSD, mescaline, and ibogaine. For more
information, please visit
https://www.magicmedindustries.com/.
Enveric Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com
Enveric Media Contacts
Caitlin
Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 516.779.2630
ckasunich@kcsa.com / rcona@kcsa.com
MagicMed Industries Contact
Natalie Dolphin
Director of Marketing
ndolphin@magicmedindustries.com
View original
content:http://www.prnewswire.com/news-releases/enveric-biosciences-and-magicmed-to-participate-in-june-2021-investor-and-industry-conferences-301304765.html
SOURCE Enveric Biosciences